Literature DB >> 2068942

The definition of HIV-specific neuropathology.

H Budka1.   

Abstract

Evaluation of a neuropathological series of 160 HIV-infected patients, almost all in the terminal AIDS stage of the infection, allowed recognition of novel syndromes which can be regarded as HIV-specific neuropathology because: 1) they are not observed in non-HIV tissues; 2) HIV is, in our hands consistently by immunocytochemistry, demonstrable in large amounts within these lesions; 3) other pathogens are not detectable within these lesions; and 4) these lesions may occur in isolated fashion within CNS tissues (40% of HIV-specific neuropathology in this series), without any other CNS pathology. HIV-specific neuropathology was found in 34% in this series and comprised two prototypes within a spectrum of frequently overlapping changes: multifocal microgranulomatous lesions of HIV encephalitis, and diffuse white matter damage of HIV leukoencephalopathy. In almost all cases, multinucleated giant cells signal the local presence of HIV in routine stains. In contrast to HIV-specific neuropathology, various unspecific nervous tissue syndromes do not consistently exhibit the local presence of HIV and thus are designated HIV-associated or possibly HIV-induced lesions: lymphocytic meningitis, vacuolar myelopathy, multifocal vacuolar leukoencephalopathy, and diffuse poliodystrophy. Although these unspecific syndromes may also contribute to clinical manifestations, their pathogenetic relation with HIV remains to be established.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2068942     DOI: 10.1111/j.1440-1827.1991.tb01645.x

Source DB:  PubMed          Journal:  Acta Pathol Jpn        ISSN: 0001-6632


  9 in total

1.  Cerebrospinal fluid is an efficient route for establishing brain infection with feline immunodeficiency virus and transfering infectious virus to the periphery.

Authors:  Pinghuang Liu; Lola C Hudson; Mary B Tompkins; Thomas W Vahlenkamp; Brenda Colby; Cyndi Rundle; Rick B Meeker
Journal:  J Neurovirol       Date:  2006-08       Impact factor: 2.643

Review 2.  Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases.

Authors:  I Kadiu; J G Glanzer; J Kipnis; H E Gendelman; M P Thomas
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

3.  Spatial data analysis in the quantitative assessment of cerebral white matter pathology on MRI in HIV infection.

Authors:  R J Corrigall; W K Chong; M Paley; I D Wilkinson; P Lantos; I Everall
Journal:  Neuroradiology       Date:  1995-08       Impact factor: 2.804

Review 4.  HIV-1 Nef in macrophage-mediated disease pathogenesis.

Authors:  Susanna L Lamers; Gary B Fogel; Elyse J Singer; Marco Salemi; David J Nolan; Leanne C Huysentruyt; Michael S McGrath
Journal:  Int Rev Immunol       Date:  2012-12       Impact factor: 5.311

5.  Brain-specific HIV Nef identified in multiple patients with neurological disease.

Authors:  Susanna L Lamers; Gary B Fogel; Enoch S Liu; Andrew E Barbier; Christopher W Rodriguez; Elyse J Singer; David J Nolan; Rebecca Rose; Michael S McGrath
Journal:  J Neurovirol       Date:  2017-10-23       Impact factor: 2.643

Review 6.  HIV-associated neuropathogenesis: a systems biology perspective for modeling and therapy.

Authors:  Susanna L Lamers; Gary B Fogel; David J Nolan; Michael S McGrath; Marco Salemi
Journal:  Biosystems       Date:  2014-04-13       Impact factor: 1.973

7.  Morphine enhances Tat-induced activation in murine microglia.

Authors:  Sirosh M Bokhari; Honghong Yao; Crystal Bethel-Brown; Peng Fuwang; Rachel Williams; Navneet K Dhillon; Ramakrishna Hegde; Anil Kumar; Shilpa J Buch
Journal:  J Neurovirol       Date:  2009-05       Impact factor: 2.643

8.  Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains.

Authors:  C L Achim; M P Heyes; C A Wiley
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

Review 9.  Blood-brain barrier and retroviral infections.

Authors:  Florence Miller; Philippe V Afonso; Antoine Gessain; Pierre-Emmanuel Ceccaldi
Journal:  Virulence       Date:  2012-03-01       Impact factor: 5.882

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.